Hemato Oncology Testing Market By Service & Product (Services and Assay Kits), By Cancer Type (Leukemia (Acute myeloid leukaemia, Acute lymphocytic leukaemia and Other leukaemia (Chronic lymphocytic leukaemia, and chronic myeloid leukaemia)), Lymphoma (Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Other Cancers (Myeloma, Myelofibrosis (MF), Essential Thrombocythemia)), By Technology (PCR, IHC, NGS, Cytogenetics, and Others), By End User (Clinical laboratories, Hospitals, Academic & Research Institutes and Other End Users (CROs and Pharmaceutical & Biotechnology Companies), and By Region - Global Forecast to 2029

Hemato Oncology Testing Market accounted for USD 2.8 Billion in 2020 and is estimated to be USD 7.6 Billion by 2029 and is anticipated to register a CAGR of 11.9%

Haematology-oncology testing is the identification, precaution and treatment of cancer (oncology) and blood disease (haematology), followed by research into them. Hematology-oncology contains disorders such as iron deficiency anaemia, sickle cell disease, haemophilia, leukaemias, thalassemia and lymphomas, as well as cancers of other organs. Growth is guided by the increasing worldwide prevalence of hematologic cancer, exponential awareness concerning customized medications, and expanding alliances for maturing new tests.

Growth in the prevalence of Lymphoma & Myeloma Cancers

After non-Hodgkin’s Lymphoma and leukaemia, Multiple myeloma is categorized as the 3rd most standard configuration of haematological malignancy. Within the bone marrow, it is differentiated by the rapid propagation of duplicate plasma cells. Concerning the study carried out by Leukemia & Lymphoma Society (LLS), approximately 176,200 people in the United States were thought to have been diagnosed with myeloma, Lymphoma and leukaemia in 2019. New cases are predicted to record 10% of the reckoned 1,762,450 new cancer cases tested in the U.S. in 2019. Prevalence is the rough count of people living on a particular date in a populace who have been diagnosed with the disease. An approximate 1,399,180 people in the U.S. are either alive with or are recovering from, leukaemia, Lymphoma, or myeloma. 

Increasing focus on personalized medicine

The ideas of Personalized Medicines have been valued in medicine since its 1st mention in a title in 1998 followed by publication on the Medline interface in 1999. Evolution in genetic technologies, like single nucleotide polymorphism (SNP), genotyping and microarray/biochips have been the main driving strategy.

However, technical and clinical-related challenges might hamper the growth of the global market to a certain extent.

The global hemato oncology testing market is segmented by product & service, cancer type, technology, end user, and region.

Based on the product, the global hemato oncology testing market is segmented into assay kits and services. Based on the cancer leukemia, the target market is classified into leukemia (acute myeloid leukaemia, acute lymphocytic leukaemia, and other leukaemia (chronic lymphocytic leukaemia and, chronic myeloid leukaemia)), lymphoma (Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and other cancers (myeloma, myelofibrosis (mf), essential thrombocythemia). Based on the technology, the global market is segmented into PCR, IHC, NGS, cytogenetics, and others. Based on the end-user, it is segmented into CROs and, pharmaceutical & biotechnology companies.

Regional Insights:

According to the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to record the most considerable CAGR in the market during the prediction period. Whereas, North America dominated the market in 2018. The increase in the APAC market is operated mostly by the massive population of patients, and an increment in focusing the critical players on expansion in this region will drive the growth of the market. Moreover, the Asia Pacific will register an enormous growth rate during the prediction period (2019–2024)”

Report Scope:

Segments Covered in the Report:

This report represents the revenue growth at regional, country and global levels and serves as an interpretation of the most recent industry trends and opportunities in every sub-segment from 2019 to 2024. This study has segmented the global hemato oncology testing market by product & services, cancer leukaemia, technology, end-user & region.

Global Hemato Oncology Testing Market, by product & services:

• Services
• Assay Kits

Global Hemato Oncology Testing Market, by Cancer Type:

• Leukaemia

• Acute myeloid leukaemia
• Acute lymphocytic leukaemia
•  Other leukaemia (Chronic lymphocytic leukaemia and chronic myeloid leukaemia)

• Lymphoma

• Non-Hodgkin’s Lymphoma
• Hodgkin’s Lymphoma
• Other cancers (Myeloma, Myelofibrosis (MF))
• Essential Thrombocythemia

Global Hemato Oncology Testing Market, by Technology:

• PCR
• IHC
• NGS
• Cytogenetics
• Others

Global Hemato Oncology Testing Market, by End User:

• Clinical laboratories,
• Hospitals, Academic
• Research Institutes,
• Other End Users (CROs, Pharmaceutical & Biotechnology Companies).

Global Hemato Oncology Testing Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., MolecularMD (Ireland), Invivoscribe, Inc., Asuragen, Inc., Adaptive Biotechnologies. Companies are forming alliances to improve their product portfolio and market presence. For instance, In May 2018, Adaptive Biotechnologies (US) collaborated with Sanofi, SA. (US), to utilize Adaptive’s clonoSEQ Assay to measure MRD status in response to isatuximab.

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories 
• Thermo Fisher Scientific, Inc.
•  QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• MolecularMD
• Invivoscribe, Inc.
• Asuragen, Inc.
• Adaptive Biotechnologies